In recent years, efficient methods for facilitation of intracellular drug delivery have become a prominent need within the modern biopharmaceutical industry. Targeting the delivery of a pharmacological substance to its intended physiological site of action ensures that adequate concentration of the therapeutics is made available, in order to elicit the desired clinical benefits and limit off-target / systemic toxicity. In fact, a study suggests that over 20% of the proteome, including oncogenic proteins, cell metabolism regulators, components of different signal transduction pathways and enzymes, is localized within the cell membrane. Further, considering the fact that only 10% of the human genome can selectively bind to small molecule pharmaceuticals, industry experts believe that intracellular biologics, particularly nucleic acid-based therapeutic interventions, present a promising alternative to conventional therapies. Furthermore, recent advancements in cell biology and intracellular delivery systems have led to the identification of several potential therapeutic targets for a variety of clinical disorders. These targets have been demonstrated to be capable of aiding the treatment of disease indications which were previously considered incurable, as they were localized within the confines of the cell membrane. It is also worth highlighting that majority of the available biopharmaceutical interventions, such as gene therapies, require cell membrane permeabilization in order to mediate their therapeutic effects.
Gene delivery systems are usually based on viral and non-viral vectors and known to enable the entry of pharmacologically active compounds into the matrix of the cytoplasm. Specifically, viral drug delivery systems utilize the ability of viruses to inject their DNA inside host cells. However, such systems are often fraught with several challenges, such as immunogenicity, toxicity and reverse mutation. In order to overcome the aforementioned challenges and enable the delivery of intracellular biologics, researchers have developed various non-viral delivery systems, including exosome-based drug delivery techniques, cell-penetrating peptides (CPP) and nanoparticle-based processes. Further, numerous technology developers have signed several strategic agreements with therapy developers in order to facilitate the development of drug formulations that can be delivered to the intracellular matrix. Additionally, close to 1,300 patents related to such technologies have been filed / granted in the past few years, demonstrating the continued innovation being carried out in this domain. At present, more than 20,000 oligonucleotide-based therapeutics focused studies are being conducted across the globe. In this context, it is also worth mentioning that, recently, Novartis received the USFDA approval for Leqvio (inclisiran), a first-in-class siRNA therapy for lower LDL cholesterol, which is delivered using an intracellular drug delivery technology. Other examples of recently approved gene therapies that are being delivered intracellularly include (alphabetical order) ABECMA (idecabtagene vicleucel; manufactured by Celgene), BREYANZI (lisocabtagene maraleucel; manufactured by Juno Therapeutics) and KYMRIAH (tisagenlecleucel; manufactured by Novartis). Driven by a growing demand for systems that can efficiently deliver therapeutic interventions in intracellular spaces, the non-viral drug delivery systems market is likely to witness significant growth in the short to mid-term.
Scope of the Report
The “Non-Viral Drug Delivery Systems Market (2nd Edition), 2023-2035: Distribution by Type of Molecule Delivered (Small Molecules and Biologics), Type of Biologic Delivered (RNAi / mRNA, DNA Oligonucleotides, Antibodies, Proteins / Peptides), Type of Vehicle Used (Cell Penetrating Peptides, Extracellular Vesicles, Oligonucleotides, Nanoparticles and Polymers), Target Therapeutic Area (Infectious Diseases, Oncological Disorders, Genetic Disorders, Neurological Disorders, Hepatic Disorders, Cardiovascular Disorders and Other Disorders), Type of Payment (Upfront Payments and Milestone Payments) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts” report features an extensive study of the current landscape and the likely future opportunities of players engaged in offering intracellular drug delivery technologies in the healthcare domain, over next 12 years.
Amongst other elements, the report includes:
- An executive summary of the key insights captured during our research, offering a high-level view on the current state of the non-viral drug delivery systems market and its likely evolution in the short to mid and long term.
- A brief introduction to important concepts related to non-viral intracellular drug delivery, featuring information on various types of non-viral drug delivery systems and its primary applications in the healthcare domain, along with details related to the recent advancements that have been reported in this market space.
- A detailed review of the overall market landscape of non-viral drug delivery systems, featuring an in-depth analysis based on several relevant parameters, such as therapeutic portfolio, type of molecule delivered (small molecules and biologics), type of biologic delivered (antibodies, DNA, RNA and proteins / peptides), type of interaction (co-administration, conjugation, encapsulation and others) and type of vehicle used (cell penetrating peptides, extracellular vesicles, oligonucleotides, nanoparticles, polymers). In addition, it features a list of technology developers and a detailed analysis based on year of establishment, company size, type of company and geographical location.
- An in-depth analysis, highlighting the contemporary market trends, using four schematic representations, including a waffle chart representation, (highlighting the distribution of various types of vehicles used for delivering payloads), a heat map representation (based on company size and type of molecule delivered), a vertical stacked column bar chart representation (location of headquarters and type of service provider), a vertical column clustered chart representation (based on company size and location of headquarters).
- An insightful company competitiveness analysis of non-viral drug delivery systems providers, taking into consideration various relevant parameters, such as years of experience and portfolio strength (in terms of number of technologies offered, type of biologics delivered and type of linkage) and partnership strength (in terms of number of partnerships, partnership year, partnerships based on geographies, type of partnerships, therapeutic area, payment portfolio and type of biologics delivered).
- Elaborate profiles of prominent players engaged in offering non-viral drug delivery technologies, across North America, Europe and Asia. Each company profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and key members of the executive team), details related to its recent developments and an informed future outlook.
- An in-depth analysis of the various patents that have been filed / granted patent related to intracellular drug delivery technologies, based on various parameters, such as type of patent, publication year, granted patents, filed patents, patent publication year and type of players, issuing authority, patent focus, patent age and CPC symbols (in terms of the size of intellectual property portfolio). Further, it features a three-dimensional bubble analysis (based on patent citation count, publication year and extended geographical reach), patent benchmarking analysis and a detailed patent valuation analysis
- An insightful analysis of various partnerships inked between stakeholders engaged within the non-viral drug delivery domain, based on several relevant parameters, such as year of partnership, type of partner (industry and non-industry), type of partnership (Research and Development, Research, development and commercialization, product development, product development and commercialization, product development and manufacturing, product development and manufacturing, commercialization, manufacturing, acquisition / merger and others), purpose of partnership (technology licensing agreements, technology evaluation agreements, technology integration agreements, technology utilization agreements, acquisitions / mergers and others), therapeutic area (oncological disorders, infectious diseases, genetic disorders, hepatic disorders, neurological disorders, cardiovascular disorders, ophthalmic diseases, pulmonary diseases, metabolic disorders, immunological disorders and others), type of payment model (upfront payments, milestone payments, royalties and others), type of molecule delivered (small molecules, biologics and both), type of biologic delivered (antibodies, RNA, DNA and proteins / peptides), most active players (in terms of number of deals inked), most popular technologies (in terms of number of deals inked for technologies) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2015-2022.
- An insightful framework which provides four zones of evaluation and product portfolio matrix based on various parameters, such as number of drugs in the pipeline, number of companies, deal amount, partnership activity, trends highlighted in number of grants, number of publications, google hits and qualitative scoring. It also provides a Kalbach, Ansoff and BCG matrix for respective non-viral drug delivery technologies currently employed by stakeholders.
One of the key objectives of this report was to estimate the existing market opportunity and the future growth potential of the non-viral drug delivery market over the coming years. We have provided an informed estimate on the likely financial evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and upcoming opportunity segmented across important parameters, such as type of molecule delivered (small molecules and biologics), type of biologic delivered (antibodies, RNA, DNA and proteins / peptides), type of vehicle used (Cell Penetrating Peptides, Extracellular Vesicles, Oligonucleotides, Nanoparticles and Polymers), target therapeutic area (infectious diseases, oncological disorders, genetic disorders, neurological disorders, hepatic disorders, cardiovascular disorders and other disorders), type of payment model (upfront payments and milestone payments) and key geographical regions (North America, Europe, Asia, Latin America, Middle East and North Africa and rest of the world).
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Frequently Asked Questions
- Who are the leading players engaged in the development of intracellular drug delivery technologies?
- Which partnership models are commonly adopted by stakeholders engaged in this domain?
- What type of molecule can be delivered using intracellular drug delivery technologies?
- How is the intellectual property landscape related to intracellular drug delivery likely to evolve in the foreseen future?
- How is the current and future market opportunity likely to be distributed across key market segments and geographical region?
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Market Segmentations
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Need for Targeted Drug Delivery
3.3. Advanced Approaches for Delivery of Drug Payloads
3.3.1. Nanoparticle Delivery Systems
3.3.1.1. Liposomes
3.3.1.2. Nanoparticles / Microparticles
3.3.1.3. PEGylation
3.3.1.4. Cell Penetrating Peptides (CPPs)
3.3.2. Other Drug Delivery Technologies
3.4. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Intracellular Drug Delivery: List of Technologies
4.2.1. Analysis by Type of Molecule Delivered
4.2.2. Analysis by Type of Biologic Delivered
4.2.3. Analysis by Type of Interaction
4.2.4. Analysis by Therapeutic Portfolio
4.3. Intracellular Drug Delivery: List of Technology Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Company
4.3.4. Analysis by Location of Headquarters (By Region)
5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Analysis by Type of Vehicle Used
5.3. Analysis by Company Size and Type of Molecule Delivered
5.4. Analysis by Location of Headquarters (Region-wise) and Type of Service Provider
5.5. Analysis by Company Size and Location of Headquarters
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: Benchmarking of Portfolio Strength
6.5. Company Competitiveness Analysis: Benchmarking of Partnership Strength
6.5.1. Company Competitiveness Analysis: Very Small Companies
6.5.2. Company Competitiveness Analysis: Small Companies
6.5.3. Company Competitiveness Analysis: Mid-Sized Companies
6.5.4. Company Competitiveness Analysis: Large and Very Large Companies
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Arcturus Therapeutics
7.2.1. Company Overview
7.2.2. Technology Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. Bio-Path Holdings
7.3.1. Company Overview
7.3.2. Technology Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. CureVac
7.4.1. Company Overview
7.4.2. Technology Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. Entos Pharmaceuticals
7.5.1. Company Overview
7.5.2. Technology Portfolio
7.5.3. Recent Developments and Future Outlook
7.6. eTheRNA
7.6.1. Company Overview
7.6.2. Technology Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Matinas BioPharma
7.7.1. Company Overview
7.7.2. Technology Portfolio
7.7.3. Recent Developments and Future Outlook
7.8. MDimune
7.8.1. Company Overview
7.8.2. Technology Portfolio
7.8.3. Recent Developments and Future Outlook
7.9. PCI Biotech
7.9.1. Company Overview
7.9.2. Technology Portfolio
7.9.3. Recent Developments and Future Outlook
8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Non-Viral Intracellular Drug Delivery Technologies: Patent Analysis
8.3.1. Analysis by Type of Patent
8.3.2. Analysis by Publication Year
8.3.3. Analysis by Application Year
8.3.4. Analysis by Cumulative Number of Annual Granted Patents
8.3.5. Analysis by Cumulative Number of Annual Patent Applications
8.3.6. Analysis by Issuing Authority
8.3.7. Analysis by Type of Player
8.3.8. Leading Players: Analysis by Number of Patents
8.3.9. Leading Inventors: Analysis by Number of Patents
8.3.10. Analysis by Top Sections
8.3.11. Intracellular Drug Delivery Technologies: Patent Benchmarking Analysis
8.4. Intracellular Drug Delivery Technologies: Patent Valuation Analysis
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Intracellular Drug Delivery Technologies: List of Partnerships and Collaborations
9.3.1. Cumulative Analysis of Partnerships by Year, 2015-2022
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership, 2015-2022
9.3.4. Analysis by Purpose of Partnership
9.3.5. Analysis by Type of Molecule Delivered
9.3.6. Analysis by Type of Biologic Delivered
9.3.7. Analysis by Target Therapeutic Area
9.3.8. Analysis by Type of Payment Model Employed
9.3.9. Analysis by Year of Partnership and Type of Payment Model Employed, 2015-2022
9.3.10 Analysis by Year of Partnership and Type of Company, 2015-2022
9.3.11. Analysis by Purpose of Partnership and Type of Company
9.3.12. Most Active Players: Analysis by Number of Partnerships
9.3.13. Most Popular Technologies: Analysis by Number of Partnerships
9.3.14. Analysis by Region
9.3.15. Local and International Agreements
9.3.16. Intracontinental and Intercontinental Agreements
10. PUBLISHER FRAMEWORK: BCG, ANSOFF AND KALBACH INNOVATION MODEL
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3 Input Parameters
10.3.1. Research Activity
10.3.2. Government Support
10.3.3. Partnership Activity
10.3.4. Global Competition
10.3.4.1. Technology-wise Competition
10.3.4.2. Drug-wise Competition
10.3.5. Google Hits
10.3.6. Opportunity Assessment
10.3.7. Other Qualitative Inputs based on Secondary and Primary Research
10.4. Output Analysis
10.4.1. BCG Matrix Model
10.4.2. Ansoff Matrix Model
10.4.3. Kalbach Innovation Model
10.5. Concluding Remarks
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions
11.3. Forecast Methodology
11.4. Global Non-Viral Intracellular Drug Delivery Technologies Market, 2022-2035
11.5. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed, 2022 and 2035
11.5.1 Non-Viral Intracellular Drug Delivery Technologies Market for Upfront Payments, 2022-2035
11.5.2 Non-Viral Intracellular Drug Delivery Technologies Market for Milestone Payments, 2022-2035
11.6. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered, 2022 and 2035
11.6.1 Non-Viral Intracellular Drug Delivery Technologies Market for Small Molecules, 2022-2035
11.6.2 Non-Viral Intracellular Drug Delivery Technologies Market for Biologics, 2022-2035
11.7. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Biologic Delivered, 2022 and 2035
11.7.1 Non-Viral Intracellular Drug Delivery Technologies Market for Antibodies, 2022-2035
11.7.2 Non-Viral Intracellular Drug Delivery Technologies Market for RNA, 2022-2035
11.7.3 Non-Viral Intracellular Drug Delivery Technologies Market for DNA, 2022-2035
11.7.4 Non-Viral Intracellular Drug Delivery Technologies Market for Proteins / Peptides, 2022-2035
11.8. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Vehicle Used, 2022 and 2035
11.8.1. Non-Viral Intracellular Drug Delivery Technologies Market for Cell Penetrating Peptides, 2022-2035
11.8.2 Non-Viral Intracellular Drug Delivery Technologies Market for Extracellular Vesicles, 2022-2035
11.8.3 Non-Viral Intracellular Drug Delivery Technologies Market for Nanoparticles, 2022-2035
11.8.4 Non-Viral Intracellular Drug Delivery Technologies Market for Oligonucleotides, 2022-2035
11.8.5 Non-Viral Intracellular Drug Delivery Technologies Market for Polymers, 2022-2035
11.9. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Target Therapeutic Area, 2022 and 2035
11.9.1 Non-Viral Intracellular Drug Delivery Technologies Market for Infectious Diseases, 2022-2035
11.9.2 Non-Viral Intracellular Drug Delivery Technologies Market for Oncological Disorders, 2022-2035
11.9.3 Non-Viral Intracellular Drug Delivery Technologies Market for Genetic Disorders, 2022-2035
11.9.4 Non-Viral Intracellular Drug Delivery Technologies Market for Neurological Disorders, 2022-2035
11.9.5 Non-Viral Intracellular Drug Delivery Technologies Market for Hepatic Disorders, 2022-2035
11.9.6 Non-Viral Intracellular Drug Delivery Technologies Market for Cardiovascular Disorders 2022-2035
11.9.7 Non-Viral Intracellular Drug Delivery Technologies Market for Other Disorders, 2022-2035
11.10. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Geography, 2022 and 2035
11.10.1. Non-Viral Intracellular Drug Delivery Technologies Market in North America, 2022-2035
11.10.2. Non-Viral Intracellular Drug Delivery Technologies Market in Europe, 2022-2035
11.10.3. Non-Viral Intracellular Drug Delivery Technologies Market in Asia, 2022-2035
11.10.4. Non-Viral Intracellular Drug Delivery Technologies Market in Latin America, 2022-2035
11.10.5. Non-Viral Intracellular Drug Delivery Technologies Market in Middle East and North Africa, 2022-2035
11.10.6. Non-Viral Intracellular Drug Delivery Technologies Market in Rest of the World, 2022-2035
12. CONCLUDING REMARKS
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Biond Biologics
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Tehila BenMoshe, Chief Executive Officer and Itay Friedman, Vice President Clinical Development
13.3. Carmine Therapeutics
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Don Haut, Chief Executive Officer
13.4. Eyevensys
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Thierry Bordet, Chief Scientific Officer
13.5. Generation Bio
13.5.1. Company Snapshot
13.5.2. Interview Transcript: Maren Killackey, Senior Director, Investor Relations and Communications
13.6. PCI Biotech
13.6.1. Company Snapshot
13.6.2. Interview Transcript: Anders Høgset, Research Director / Chief Scientific Officer
13.7. SRI International
13.7.1. Company Snapshot
13.7.2. Interview Transcript: Melissa Wagner, Strategic Business Executive, Biosciences Division
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 3.1 Mechanisms of Drug Transport Through Intestinal Epithelium
Figure 4.1 Non-Viral Intracellular Drug Delivery Technologies: Distribution by Type of Molecule Delivered
Figure 4.2 Non-Viral Intracellular Drug Delivery Technologies: Distribution by Type of Biologic Delivered
Figure 4.3 Non-Viral Intracellular Drug Delivery Technologies: Distribution by Type of Interaction
Figure 4.4 Non-Viral Intracellular Drug Delivery Technology Providers: Most Active Player Based on Therapeutic Portfolio
Figure 4.5 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Year of Establishment
Figure 4.6 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Company Size
Figure 4.7 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Type of Company
Figure 4.8 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Location of Headquarters (By Region)
Figure 5.1 Key Insights: Distribution by Type of Vehicle Used (Waffle Chart Representation)
Figure 5.2 Key Insights: Distribution by Company Size and Type of Molecule Delivered (Heat Map Representation)
Figure 5.3 Key Insights: Distribution by Location of Headquarters (Region-wise) and Type of Service Provider (Vertical Stacked Column Chart)
Figure 5.4 Key Insights: Distribution by Company Size and Location of Headquarters (Vertical Clustered Column Chart)
Figure 6.1 Company Competitiveness Analysis: Benchmarking of Product Portfolio
Figure 6.2 Company Competitiveness Analysis: Benchmarking of Partnership Strength
Figure 6.3 Company Competitiveness Analysis: Very Small Companies
Figure 6.4 Company Competitiveness Analysis: Small Companies
Figure 6.5 Company Competitiveness Analysis: Mid-sized Companies
Figure 6.6 Company Competitiveness Analysis: Large and Very Large Companies
Figure 8.1 Intracellular Drug Delivery Technologies: Patent Analysis
Figure 8.2 Patent Analysis: Distribution by Type of Patent
Figure 8.3 Patent Analysis: Distribution by Publication Year
Figure 8.4 Patent Analysis: Distribution by Application Year
Figure 8.5 Patent Analysis: Distribution by Cumulative Number of Granted Patents
Figure 8.6 Patent Analysis: Distribution by Cumulative Number of Patent Applications
Figure 8.7 Patent Analysis: Distribution by Issuing Authority
Figure 8.8 Patent Analysis: Distribution by Type of Player
Figure 8.9 Leading Players: Distribution by Number of Patents
Figure 8.10 Leading Inventors: Distribution by Number of Patents
Figure 8.11 Patent Analysis: Distribution by CPC Symbols
Figure 8.12 Intracellular Drug Delivery Technologies: Patent Benchmarking Analysis
Figure 8.13 Intracellular Drug Delivery Technologies: Patent Valuation Analysis
Figure 8.18 Patent Analysis: Leading Patents: Analysis by Number of Citations
Figure 9.1 Partnerships and Collaborations: Cumulative Distribution of Partnerships by Year, 2015-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2022
Figure 9.4 Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Molecule Delivered
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Biologic Delivered
Figure 9.7 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 9.8 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner 2015-2022
Figure 9.9 Partnerships and Collaborations: Purpose of Partnership and Type of Company
Figure 9.10 Most Active Players: Distribution by Number of Partnerships
Figure 9.11 Most Popular Technologies: Distribution by Number of Partnerships
Figure 9.12 Partnerships and Collaborations: Distribution by Region
Figure 9.13 Partnerships and Collaborations: Distribution by Type of Payment Model Employed
Figure 9.14 Partnerships and Collaborations: Distribution by Year of Partnership, Type of Payment Model Employed and Amount Raised (USD Million)
Figure 9.15 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 9.16 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Figure 10.1 Publisher Framework: Trends in Publication
Figure 10.2 Publisher Framework: Trend in Grants
Figure 10.3 Publisher Framework: Trends in Partnership Activity
Figure 10.4 Publisher Framework: Trends in Number of Technologies, Drugs and Deal Amount
Figure 10.5 Publisher Framework: Trends in Google Hits
Figure 10.6 BCG Matrix Model
Figure 10.7 Ansoff Matrix Model
Figure 10.8 Kalbach Innovation Model
Figure 11.1 Global Non-Viral Intracellular Drug Delivery Technologies Market, 2022-2035 (USD Million)
Figure 11.2 Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Type of Payment Model Employed, 2022 and 2035
Figure 11.3 Non-Viral Intracellular Drug Delivery Technologies Market for Upfront Payments, 2022-2035 (USD Million)
Figure 11.4 Non-Viral Intracellular Drug Delivery Technologies Market for Milestone Payments, 2022-2035 (USD Million)
Figure 11.5 Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Type of Molecule Delivered, 2022 and 2035
Figure 11.6 Non-Viral Intracellular Drug Delivery Technologies Market for Small Molecules, 2022-2035 (USD Million)
Figure 11.7 Non-Viral Intracellular Drug Delivery Technologies Market for Biologics, 2022-2035 (USD Million)
Figure 11.8 Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Type of Biologic Delivered, 2022 and 2035
Figure 11.9 Non-Viral Intracellular Drug Delivery Technologies Market for Antibodies, 2022-2035 (USD Million)
Figure 11.10 Non-Viral Intracellular Drug Delivery Technologies Market for RNA, 2022-2035 (USD Million)
Figure 11.11 Non-Viral Intracellular Drug Delivery Technologies Market for DNA, 2022-2035 (USD Million)
Figure 11.12 Non-Viral Intracellular Drug Delivery Technologies Market for Proteins / Peptides, 2022-2035 (USD Million)
Figure 11.13 Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Type of Vehicle Used, 2022 and 2035
Figure 11.14 Non-Viral Intracellular Drug Delivery Technologies Market for Cell Penetrating Peptides, 2022-2035 (USD Million)
Figure 11.15 Non-Viral Intracellular Drug Delivery Technologies Market for Extracellular Vesicles, 2022-2035 (USD Million)
Figure 11.16 Non-Viral Intracellular Drug Delivery Technologies Market for Oligonucleotides, 2022-2035 (USD Million)
Figure 11.17 Non-Viral Intracellular Drug Delivery Technologies Market for Nanoparticles, 2022-2035 (USD Million)
Figure 11.18 Non-Viral Intracellular Drug Delivery Technologies Market for Polymers, 2022-2035 (USD Million)
Figure 11.19 Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Target Therapeutic Areas, 2022 and 2035
Figure 11.20 Non-Viral Intracellular Drug Delivery Technologies Market for Infectious Diseases, 2022-2035 (USD Million)
Figure 11.21 Non-Viral Intracellular Drug Delivery Technologies Market for Oncological Disorders, 2022-2035 (USD Million)
Figure 11.22 Non-Viral Intracellular Drug Delivery Technologies Market for Genetic Disorders, 2022-2035 (USD Million)
Figure 11.23 Non-Viral Intracellular Drug Delivery Technologies Market for Neurological Disorders, 2022-2035 (USD Million)
Figure 11.24 Non-Viral Intracellular Drug Delivery Technologies Market for Hepatic Disorders, 2022-2035 (USD Million)
Figure 11.25 Non-Viral Intracellular Drug Delivery Technologies Market for Cardiovascular Disorders, 2022-2035 (USD Million)
Figure 11.26 Non-Viral Intracellular Drug Delivery Technologies Market for Other Disorders, 2022-2035 (USD Million)
Figure 11.27 Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Geography, 2022 and 2035
Figure 11.28 Non-Viral Intracellular Drug Delivery Technologies Market in North America, 2022-2035 (USD Million)
Figure 11.29 Non-Viral Intracellular Drug Delivery Technologies Market in Europe, 2022-2035 (USD Million)
Figure 11.30 Non-Viral Intracellular Drug Delivery Technologies Market in Asia, 2022-2035 (USD Million)
Figure 11.31 Non-Viral Intracellular Drug Delivery Technologies Market in Latin America, 2022-2035 (USD Million)
Figure 11.32 Non-Viral Intracellular Drug Delivery Technologies Market in Middle East and North Africa, 2022-2035 (USD Million)
Figure 11.33 Non-Viral Intracellular Drug Delivery Technologies Market in Rest of the World, 2022-2035 (USD Million)
List Of Tables
Table 4.1 List of Non-Viral Intracellular Drug Delivery Technologies
Table 4.2 Non-Viral Intracellular Drug Delivery Technologies: Information on Type of Biologic Delivered
Table 4.3 List of Non-Viral Intracellular Drug Delivery Technology Developers
Table 6.1 Company Competitiveness Analysis: Benchmarking of Product Portfolio
Table 6.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Table 7.1 List of Companies Profiled
Table 7.2 Arcturus Therapeutics: Company Overview
Table 7.3 Technology Profile: LUNAR®
Table 7.4 Arcturus Therapeutics: Recent Developments and Future Outlook
Table 7.5 Bio-Path Holdings: Company Overview
Table 7.6 Technology Profile: DNAbilize®
Table 7.7 Bio-Path: Recent Developments and Future Outlook
Table 7.8 CureVac: Company Overview
Table 7.9 Technology Profile: mRNA technology
Table 7.10 CureVac: Recent Developments and Future Outlook
Table 7.11 Entos Pharmaceuticals: Company Overview
Table 7.12 Technology Profile: Fusogenix
Table 7.13 Entos Pharmaceuticals: Recent Developments and Future Outlook
Table 7.14 eTheRNA immunotherapies: Company Overview
Table 7.15 Technology Profile: TriMix technology
Table 7.16 eTheRNA immunotherapies: Recent Developments and Future Outlook
Table 7.17 Matinas Biopharma: Company Overview
Table 7.18 Technology Profile: LNC Platform
Table 7.19 Matinas Biopharma: Recent Developments and Future Outlook
Table 7.20 MDimune: Company Overview
Table 7.21 Technology Profile: BioDrone
Table 7.22 MDimune: Recent Developments and Future Outlook
Table 7.23 PCI Biotech: Company Overview
Table 7.24 Technology Profile: Photochemical internalisation
Table 7.25 PCI Biotech: Recent Developments and Future Outlook
Table 8.1 Patent Analysis: Top Sections
Table 8.2 Patent Analysis: Top Symbols
Table 8.3 Patent Analysis: Top Codes
Table 8.4 Patent Portfolio: Summary of Benchmarking Analysis
Table 8.5 Patent Analysis: Categorization Based on Weighted Valuation Score
Table 8.6 Patent Analysis: List of Relatively Higher Value Patents
Table 9.1 Non-Viral Intracellular Drug Delivery Technologies: Partnerships and Collaborations, 2015-2022
Table 13.1 Biond Biologics: Company Snapshot
Table 13.2 Carmine Therapeutics: Company Snapshot
Table 13.3 Eyevensys: Company Snapshot
Table 13.4 Generation Bio: Company Snapshot
Table 13.5 PCI Biotech: Company Snapshot
Table 13.6 SRI International: Company Snapshot
Table 14.1 Non-Viral Intracellular Drug Delivery Technologies: Distribution by Type of Molecule Delivered
Table 14.2 Non-Viral Intracellular Drug Delivery Technologies: Distribution by Type of Biologic Delivered
Table 14.3 Non-Viral Intracellular Drug Delivery Technologies: Distribution by Type of Interaction
Table 14.4 Non-Viral Intracellular Drug Delivery Technology Providers: Most Active Player Based on Therapeutic Portfolio
Table 14.5 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Year of Establishment
Table 14.6 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Company Size
Table 14.7 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Type of Company
Table 14.8 Non-Viral Intracellular Drug Delivery Technology Providers: Distribution by Location of Headquarters (By Region)
Table 14.9 Key Insights: Distribution by Type of Vehicle Used
Table 14.10 Key Insights: Distribution by Company Size and Type of Molecule Delivered
Table 14.11 Key Insights: Distribution by Location of Headquarters (Region-wise) and Type of Service Provider
Table 14.12 Key Insights: Distribution by Company Size and Location of Headquarters
Table 14.13 Company Competitiveness Analysis: Benchmarking of Service Strength
Table 14.14 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Table 14.15 Company Competitiveness Analysis: Very Small Companies
Table 14.16 Company Competitiveness Analysis: Small Companies
Table 14.17 Company Competitiveness Analysis: Mid-Sized Companies
Table 14.18 Company Competitiveness Analysis: Large and Very Large Companies
Table 14.19 Intracellular Drug Delivery Technologies: Patent Analysis
Table 14.20 Patent Analysis: Distribution by Type of Patent
Table 14.21 Patent Analysis: Distribution by Publication Year
Table 14.22 Patent Analysis: Distribution by Application Year
Table 14.23 Patent Analysis: Distribution by Cumulative Number of Granted Patents
Table 14.24 Patent Analysis: Distribution by Cumulative Number of Patent Applications
Table 14.25 Patent Analysis: Distribution by Issuing Authority
Table 14.26 Patent Analysis: Distribution by Type of Player
Table 14.27 Leading Players: Analysis by Number of Patents
Table 14.28 Leading Inventors: Analysis by Number of Patents
Table 14.29 Patent Analysis: Distribution by CPC Symbols
Table 14.30 Intracellular Drug Delivery Technologies: Patent Benchmarking Analysis
Table 14.31 Intracellular Drug Delivery Technologies: Patent Valuation Analysis
Table 14.32 Partnerships and Collaborations: Cumulative Year-wise Trend of Partnerships, 2015-2022
Table 14.33 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.34 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership, 2015-2022
Table 14.35 Partnerships and Collaborations: Distribution by Purpose of Partnership
Table 14.36 Partnerships and Collaborations: Distribution by Type of Molecule Delivered
Table 14.37 Partnerships and Collaborations: Distribution by Biologic Delivered
Table 14.38 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 14.39 Partnerships and Collaborations: Type of Payment Model Employed
Table 14.40 Partnerships and Collaborations: Year of Partnership and Type of Payment Model Employed, 2015-2022
Table 14.41 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner 2015-2022
Table 14.42 Most Active Players: Distribution by Purpose of Partnership and Type of Company
Table 14.43 Most Active Players: Distribution by Number of Partnerships
Table 14.44 Most Popular Technologies: Distribution by Region
Table 14.45 Partnerships and Collaborations: Distribution by Year of Partnership, Type of Payment Model Employed and Amount Raised (USD million)
Table 14.46 Partnerships and Collaborations: Local and International Agreements
Table 14.47 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 14.48 Global Non-Viral Intracellular Drug Delivery Technologies Market, 2022-2035 Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.49 Global Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Type of Payment Model Employed, 2022 and 2035
Table 14.50 Global Non-Viral Intracellular Drug Delivery Technologies Market for Upfront Payments, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.51 Global Non-Viral Intracellular Drug Delivery Technologies Market for Milestone Payments, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.52 Global Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Type of Molecule Delivered, 2022 and 2035
Table 14.53 Global Non-Viral Intracellular Drug Delivery Technologies Market for Small Molecule, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.54 Global Non-Viral Intracellular Drug Delivery Technologies Market for Biologics, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.55 Global Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Type of Biologic Delivered, 2022 and 2035
Table 14.56 Global Non-Viral Intracellular Drug Delivery Technologies Market for Antibodies, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.57 Global Non-Viral Intracellular Drug Delivery Technologies Market for DNA, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.58 Global Non-Viral Intracellular Drug Delivery Technologies Market for Protein / Peptide, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.59 Global Non-Viral Intracellular Drug Delivery Technologies Market for RNA, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.60 Global Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Type of Vehicle Used, 2022 and 2035
Table 14.61 Global Non-Viral Intracellular Drug Delivery Technologies Market for Cell Penetrating Peptide, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.62 Global Non-Viral Intracellular Drug Delivery Technologies Market for Extracellular Vesicles, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.63 Global Non-Viral Intracellular Drug Delivery Technologies Market for Nanoparticle, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.64 Global Non-Viral Intracellular Drug Delivery Technologies Market for Oligonucleotide, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.65 Global Non-Viral Intracellular Drug Delivery Technologies Market for Polymer, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.66 Global Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Therapeutic Area, 2022 and 2035
Table 14.67 Global Non-Viral Intracellular Drug Delivery Technologies Market for Genetic Disorders, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.68 Global Non-Viral Intracellular Drug Delivery Technologies Market for Hepatic Disorders, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.69 Global Non-Viral Intracellular Drug Delivery Technologies Market for Infectious Diseases, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.70 Global Non-Viral Intracellular Drug Delivery Technologies Market for Neurological Disorders, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.71 Global Non-Viral Intracellular Drug Delivery Technologies Market for Oncological Disorders, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.72 Global Non-Viral Intracellular Drug Delivery Technologies Market for Others, 2022-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.73 Global Non-Viral Intracellular Drug Delivery Technologies Market: Distribution by Geography, 2022 and 2035
Table 14.74 Non-Viral Intracellular Drug Delivery Technologies Market in North America, 2022 and 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.75 Non-Viral Intracellular Drug Delivery Technologies Market in Europe, 2022 and 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.76 Non-Viral Intracellular Drug Delivery Technologies Market in Asia, 2022 and 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.77 Non-Viral Intracellular Drug Delivery Technologies Market in Latin America, 2022 and 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.78 Non-Viral Intracellular Drug Delivery Technologies Market in Middle East and North Africa, 2022 and 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 14.79 Non-Viral Intracellular Drug Delivery Technologies Market in Rest of the World, 2022 and 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 20Med Therapeutics
- Abcam
- Acuitas Therapeutics
- Acceleron Pharma
- Adocia
- AgonOx
- Alcobra (Acquired by Arcturus Therapeutics)
- Aldevron
- Alexion Pharmaceuticals
- Almirall
- Alnylam Pharmaceuticals
- AM Chemicals
- Amgen
- Anjarium Biosciences
- Aqdot
- Aquarius Biotechnologies
- Arcturus Therapeutics
- Arrowhead Pharmaceuticals
- Aruna Bio
- Ascendis Pharma
- Astellas Innovation Management (A subsidiary of Astellas Pharma)
- Astellas Pharma
- AstraZeneca
- Avectas
- Avellino Lab
- Avicenna Oncology
- Avidity Biosciences
- Baseceuticals (Division of Creative Biogene)
- Basilard BioTech
- Bavarian Nordic
- BeiGene
- Bicycle Therapeutics
- BioCellChallenge
- BioGene
- BioMarin Pharmaceuticals
- BioMoti
- Biond Biologics
- Bioneer
- BioNet-Asia
- BioNTech
- Biopact Ventures
- Bio-Path Holdings
- Bio-Techne
- BOC Sciences
- Carisma Therapeutics
- Carmine Therapeutics
- Catamaran Bio
- CCRM
- Celanese
- Cell and Gene Therapy Catapult
- Cellectar Biosciences
- Cellics Therapeutics
- Center for Cancer Immune Therapy (Herlev Hospital)
- Centre for Process Innovation
- CEPI
- Chimeron Bio
- Code Biotherapeutics
- Codiak BioSciences
- CQDM
- Cristal Therapeutics
- Croda
- Crucell (A subsidiary of Johnson & Johnson)
- CureVac
- Cybrexa Therapeutics
- CyGenica
- Cytiva
- DCprime (Acquired by Van Herk Investments)
- Deloitte
- Dicerna Pharmaceuticals
- Duke-NUS Medical School
- Editas Medicine
- Effimune
- Eisai
- Elasmogen
- Eli Lilly
- Emisphere Technologies
- enGene
- EnGeneIC
- Entos Pharmaceuticals
- Entrada Therapeutics
- EpiVax
- eTheRNA
- Ethris
- Evercyte
- Evox Therapeutics
- ExonanoRNA
- Eyevensys
- Feldan Therapeutics
- Frame Therapeutics (Acquired by CureVac)
- FUJIFILM Diosynth Biotechnologies
- GC Biopharma
- GenEdit
- Generation Bio
- GeneTech
- Genevant
- Genmab
- Genprex
- Genzyme
- George Mason University
- Geprex
- Glycostem Therapeutics
- GreenCross LabCell
- Gritstone bio
- GSK
- Guggenheim Securities
- Gustave Roussy
- Hansoh Pharma
- Helmholtz Zentrum München
- HK Innoen
- Hopewell Therapeutics
- ILIAS Biologics
- Image Analysis Group (IAG)
- ImmunityBio
- ImmunoForge
- IMV
- In-Cell-Art
- Incisive Genetics
- Inha University
- InnoCore Pharmaceuticals
- InnoRNA
- Innovent Biologics
- Institut Pasteur
- Intergalactic Therapeutics
- Intract Pharma
- Ionis Pharmaceuticals
- Iovance Biotherapeutics
- iTeos Therapeutics
- Janssen Pharmaceuticals
- Jazz Pharmaceuticals
- JW Pharmaceutical
- Kinos Medical
- Kite Pharma (A Gilead Company)
- Kodikaz Therapeutics
- Kyungpook National University
- Larimar Therapeutics
- Leeyeon Pharmaceutical
- LegoChem Biosciences
- LGC
- Libera Bio
- Lions Eye Institute
- Luminary Therapeutics
- Mallinckrodt Pharmaceuticals
- Matinas BioPharma
- McKinsey & Company
- MDimune
- Medicines Patent Pool
- Medigene
- MedinCell
- Mediphage Bioceuticals
- Mekonos
- Merck
- Millendo Therapeutics
- MirImmune
- University of Münster
- Myeloid Therapeutics
- Mymetics
- myNEO
- Myosana Therapeutics
- Myotonic Dystrophy Foundation
- N4 Pharma
- NanoDe Therapeutics
- Nanomerics
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- National University of Singapore
- Nature Technology Corporation
- Navigo Proteins
- Neochromosome
- NeoCura
- Neurimmune
- Novartis
- Novo Nordisk
- Novochizol
- Oisin Biotechnologies
- OliX Pharmaceuticals
- Onconova Therapeutics
- ONK Therapeutics
- Orion
- Osong Advanced Medical Foundation
- Ovensa
- Pacira BioSciences
- PAGS
- Pantherna Therapeutics
- PCI Biotech
- PeptiDream
- Pfizer
- Phio Pharmaceutials
- pHion Therapeutics
- PLx Pharma
- Poseida Therapeutics
- Precigen
- Precision NanoSystems
- PROVIREX
- PYC Therapeutics
- R&D Systems (A Bio-Techne brand)
- Ragon Institute
- Reach Regulation
- Regeneron
- ReNeuron
- Rexahn Pharmaceuticals
- Reyon Pharmaceutical
- RNAimmune
- Roche
- RXi Pharmaceuticals
- SalioGen Therapeutics
- Samsung Seoul Hospital
- Sandoz (A Novartis Division)
- Sanofi-Aventis Deutschland
- Sapreme Technologies
- Sarepta Therapeutics
- Seoul National University
- Seqirus
- Shire
- Silence Therapeutics
- Sirnaomics
- SiSaf
- Sixfold Bioscience
- SmartPharm Therapeutics
- SomaServe
- SRI International
- Starpharma
- Synthetic Genomics
- Taiba Healthcare
- Takeda Pharmaceuticals
- Tetra Bio-Pharma
- The University of Texas MD Anderson Cancer Center
- Théa Open Innovation
- Thomas Jefferson University
- Tianjin Chase Sun Pharmaceutical
- Tonghua Dongbao
- Translate Bio
- Tyris Tx
- Ultimovacs
- Ultragenyx Pharmaceutical
- University of Aberdeen
- University of California (The Simon Lab)
- University of L'Aquila
- University of Oxford
- University of Pittsburgh
- University of Texas Southwestern Medical Center
- Verve Therapeutics
- Vesigen Therapeutics
- ViiV Healthcare
- Vingroup
- Vir Biotechnology
- Vrije Universiteit Brussel (VUB)
- Vycellix
- Wisconsin Alumni Research Foundation (WARF)
- YiPSCELL
- Yuhan
- Zhejiang Haichang Biotechnology
Methodology
LOADING...
